Alendronate (Alendronate Sodium)

Subscribe to Selected New Research on Alendronate

1118 relevant articles (144 outcomes, 300 trials/studies) found for this Drug

Description: A nonhormonal medication for the treatment of postmenopausal osteoporosis in women. This drug builds healthy bone, restoring some of the bone loss as a result of osteoporosis.

Also Known As:

Alendronate Sodium; Fosamax; 4-Amino-1-Hydroxybutylidene 1,1-Biphosphonate; Alendronate Monosodium Salt, Trihydrate; Aminohydroxybutane Bisphosphonate; MK-217; 4 Amino 1 Hydroxybutylidene 1,1 Biphosphonate; Bisphosphonate, Aminohydroxybutane; MK 217; MK217; Sodium, Alendronate

Relationship Network

Drug Context: Research Results

Organic Chemicals: 40

Organophosphorus Compounds: 126

Diphosphonates: 2715

Alendronate: 1118

Maxmarvil: 1

(3-amino-1-(dimethoxyphosphoryl)-1-hydroxypropyl)phosphonic acid dimethyl ester

N-myristoylalendronic acid

prolyl-phenylalanyl-alendronate

technetium Tc 99m alendronate

Experts

1.	Iwamoto, Jun: 13 articles (02/2008 - 06/2003)
2.	Takeda, Tsuyoshi: 12 articles (02/2008 - 06/2003)
3.	Sato, Yoshihiro: 11 articles (02/2008 - 08/2004)
4.	Uzawa, Mitsuyoshi: 9 articles (02/2008 - 06/2003)
5.	Greenspan, Susan L: 8 articles (09/2008 - 05/2002)
6.	de Papp, Anne E: 6 articles (07/2006 - 10/2002)
7.	Bilezikian, John P: 5 articles (09/2008 - 09/2003)
8.	Miller, Paul D: 5 articles (01/2008 - 05/2002)
9.	Ringe, J D: 5 articles (11/2007 - 11/2001)
10.	Black, Dennis M: 5 articles (07/2007 - 09/2003)

Related Diseases

1.	Osteoporosis 07/01/2000 - "Recent results from the first megatrial of osteoporosis with >6400 participants, the Fracture Intervention Trial (FIT), have provided important advances in our understanding of osteoporosis and the efficacy of alendronate" 01/01/2000 - "As there are no proven safe and effective treatments available for men with osteoporosis, we compared the effects of alendronate (10 mg/day) on BMD, measured using dual-energy X-ray absorptiometry, in a 12-month prospective, controlled, open label study involving (i) men with primary (n = 23) or secondary osteoporosis (n = 18), (ii) postmenopausal women with primary (n = 18) or secondary (n = 21) osteoporosis, and (iii) 29 male and 14 female untreated controls matched by age, height and weight" 07/01/2006 - "Although alendronate treatment for the prevention of osteoporotic fracture has been considered to be first line treatment, there is little knowledge whether very old osteoporosis should be treated with alendronate or not" 11/01/2003 - "Alendronate (bisphosphonate) has proven its efficacy for the treatment of osteoporosis of the lumbar spine and femoral neck" 07/01/2001 - "In summary, this is the first report indicating that treatment with alendronate was able to significantly increase BMD at the lumbar spine in GHD patients with osteoporosis receiving stable rhGH replacement for 4 yr. This increase was significantly greater in alendronate-treated patients than in patients maintained on rhGH" Order ALL the reference details at left...
2.	Postmenopausal Osteoporosis 02/01/2004 - "Alendronate has been proven to be effective in the prevention and treatment of postmenopausal osteoporosis with the recommended daily dose of 10 mg. However, a constraining requirement for dosing limited its general acceptance in treatment" 12/01/1995 - "The authors observe a significant reduction in value of the Nordin's Index (a sensible test for the screening of the "fast-losers" patients) in 10 women with post-menopausal osteoporosis after therapy with alendronate 5 mg daily per os for six months" 04/01/1999 - "Sequential measurements of stature are also valuable, and both methodologies have been used in Phase III clinical trials to assess the efficacy of alendronate to treat postmenopausal osteoporosis" 12/21/1999 - "A residual effect was seen 2 years after alendronate therapy was stopped; however, continuous alendronate treatment was more effective in preventing postmenopausal bone loss than 2 years of alendronate followed by 2 years of placebo." 01/01/2002 - "OBJECTIVE: Alendronate (10 mg daily) has been shown in long term clinical trials to be an effective treatment for postmenopausal osteoporosis" Order ALL the reference details at left...
3.	Bone Resorption 05/01/2000 - "BACKGROUND: The present study was designed to examine histopathologically whether local delivery of aminobisphosphonate (alendronate) could be effective in preventing the alveolar bone resorption associated with mucoperiosteal flaps" 08/01/2007 - "Treatment with alendronate improved trabecular volume and number by reducing bone resorption, although bone formation was also reduced through coupling of bone remodeling" 07/01/2007 - "For this reason, we conducted a study to test the effect of alendronate (ALN), an inhibitor of bone resorption, on alveolar bone mass" 05/01/2006 - "MATERIALS AND METHODS: Study 1 tested the effect of alendronate, an inhibitor of bone resorption, on alveolar bone" 01/01/2003 - "The aim of this study was to investigate whether alendronate is effective on bone formation or bone resorption" Order ALL the reference details at left...
4.	Metabolic Bone Diseases (Osteopenia) 02/01/1998 - "In summary, this study demonstrated that alendronate therapy is highly effective in counteracting the osteopenia of OVX and glucocorticoid therapy." 01/01/2007 - "In women with osteopenia, alendronate therapy may be cost effective in women with a T-score of -2.4SD in the US" 12/01/2005 - "Is alendronate therapy cost-effective for postmenopausal osteopenia?" 07/01/1997 - "This study was designed to investigate whether alendronate could prevent CsA-induced osteopenia in the rat" 09/01/2005 - "Alendronate reduced clinical and radiographic vertebral fractures in postmenopausal women with osteopenia." Order ALL the reference details at left...
5.	Pain (Aches) 11/01/2004 - "RESULTS: In contrast to placebo-treated patients (n = 20), all of the alendronate-treated patients (n = 19) exhibited a marked and sustained improvement in levels of spontaneous pain, pressure tolerance, and joint mobility, as well as a significant reduction in urinary levels of NTX at weeks 4 and 8. The improvement was maintained at week 12" 03/01/1997 - "RESULTS: In the patients treated with blind alendronate the diminution in spontaneous pain, tenderness, and swelling (circumference of the affected limb) and the improvement in motion were significantly different from baseline (p < 0.001), from those observed within the first two weeks in the control group (p < 0.01), and from week 2 to week 4 (p < 0.01)" 02/01/2006 - "A significant increase of the pain score was noted in the alendronate group (p = 0.04) in the intent-to-treat analysis but not in the per protocol analysis" 02/01/2006 - "The alendronate group showed a lower frequency of collapse of the femoral head and reported less hip pain than the control group" 03/01/2005 - "CONCLUSION: Alendronate reduces pain, improves function and retards AVN progression" Order ALL the reference details at left...

Related Drugs and Biologics

1.	risedronic acid (risedronate)
2.	Etidronic Acid (HEDP)
3.	Diphosphonates
4.	Calcium
5.	Alendronate (Alendronate Sodium)
6.	Vitamin D
7.	Calcitonin (Calcitonin, Eel)
8.	Raloxifene (Evista)
9.	1-hydroxycholecalciferol (alfacalcidol)
10.	Teriparatide (Parathar)

Related Therapies and Procedures

1.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
2.	Aftercare (After-Treatment)
3.	Transplantation (Transplant Recipients)
4.	Transplants (Transplant)
5.	Arthroplasty

Best Treatments:
Research Summary Report
on Osteoporosis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 824 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>